Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Acquisitions: 2010-2019

  • Lineage Cell Therapeutics' Acquisitions was N/A to $3.1 million in Q1 2019 from the same period last year, while for Mar 2019 it was $3.9 million, marking a year-over-year change of. This contributed to the annual value of $3.1 million for FY2019, which is N/A change from last year.
  • According to the latest figures from Q1 2019, Lineage Cell Therapeutics' Acquisitions is $3.1 million, which was up 966.05% from $292,387 recorded in Q2 2012.
  • Lineage Cell Therapeutics' 5-year Acquisitions high stood at $3.1 million for Q1 2019, and its period low was $3.1 million during Q1 2019.
  • Over the past 1 years, Lineage Cell Therapeutics' median Acquisitions value was $3.1 million (recorded in 2019), while the average stood at $3.1 million.